Premium
The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia
Author(s) -
Franco Rendrik F.,
Simões Belinda P.,
Tone Luiz G.,
Gabellini Sérgio M.,
Zago Marco A.,
Falcão Roberto P.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.03140.x
Subject(s) - methylenetetrahydrofolate reductase , odds ratio , heterozygote advantage , medicine , gastroenterology , reductase , case control study , acute lymphocytic leukemia , risk factor , genotype , genetics , leukemia , biology , gene , enzyme , lymphoblastic leukemia , biochemistry
We have determined the prevalence of methylenetetrahydrofolate reductase (MTHFR) mutations C677T and A1298C in 71 children ( 15 years) with acute lymphoblastic leukaemia (ALL) and in 71 control subjects. Odds ratio (OR) for ALL linked to MTHFR C677T was 0·4 (95% CI 0·2–0·8); for heterozygotes it was 0·5 (95% CI 0·2–0·9) and for homozygotes it was 0·3 (95%CI 0·09–0·8). MTHFR A1298C yielded an overall OR for ALL of 1·3 (95% CI: 0·7–2·6); for heterozygotes it was 1·3 (95% CI: 0·7–7·6) and for homozygotes it was 2·8 (95% CI 0·5–15·6). In conclusion, MTHFR C677T was linked to a significant 2·4‐fold decreased risk of developing childhood ALL, whereas MTHFR A1298C did not significantly affect the risk of ALL in our population.